Comprehensive Biomarker Center | GenomeWeb

Comprehensive Biomarker Center

The researchers were able to differentiate among patients with lung cancer, COPD, and health controls using the biomarkers.

Synthetic Genomics said this week that it has purchased from Febit Holding GmbH the worldwide rights to three families of patents and patent applications related to gene synthesis.

NEW YORK (GenomeWeb News) – Synthetic Genomics today announced its acquisition of the worldwide rights to three families of patents and patent applications related to synthetic genomic technologies from Germany's Febit Holding.

The team is currently seeking investors and partners in order to spin out a new company and set up a facility for the gene synthesis service, which it believes it could begin offering within the next one to two years at a price of 6 to 9 cents per base pair.

The cuts were necessary to take advantage of a "window of opportunity" in miRNA discovery that could enable the firm to enter the molecular diagnostics market.

A Febit official cited competition from larger companies, as well as the declining costs of whole-genome sequencing, which would eventually replace targeted resequencing, as reasons for discontinuing its sequence-capture and sequencing services businesses.

Paired Ends


Alan Sherr, Hartmut Voss, Cord Stähler, Sandeep Nayyar, Lee Hood, Alison Symington

As a result of the restructuring, its workforce has been reduced by 60 percent and its CEO and President has left the company.

IP Roundup


Biodot, Grace Bio-Labs, Autogenomics, Febit, SRU Biosystems, University of Illinois, Columbia University, New York University

New Product Watch


Affymetrix's Axiom Genome-Wide ASI Array, Febit's Geniom miRNA Biochips, Fluidigm's Access Array System


In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.